EurekaMag.com logo
+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma



Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma



Journal of Neuropathology and Experimental Neurology 67(7): 720-727



Primary lymphomas of the CNS (PCNSLs) show molecular features of the late germinal center exit B-cell phenotype and are impaired in their terminal differentiation as indicated by a lack of immunoglobulin class switching. Because the positive regulatory domain I protein with ZNF domain (PRDM1/BLIMP1) is a master regulator of terminal B-cell differentiation into plasma cells, we investigated a series of 21 PCNSLs for the presence of mutations in the PRDM1 gene and alterations in the expression pattern of the PRDM1 protein. Direct sequencing of all coding exons of the PRDM1 gene identified deleterious mutations associated with abrogation of PRDM1 protein expression in 4 of 21 (19%) PCNSLs. Thus, similar to systemic diffuse large B-cell lymphomas, PRDM1 may be a tumor suppressor in some PCNSL and contribute to lymphomagenesis by impairing terminal differentiation.

(PDF emailed within 0-6 h: $19.90)

Accession: 033119814

Download citation: RISBibTeXText

PMID: 18596541

DOI: 10.1097/NEN.0b013e31817dd02d



Related references

Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Annals of Neurology 63(5): 662-667, 2008

Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. Journal of Neuropathology and Experimental Neurology 65(8): 776-782, 2006

Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal of Neuro-Oncology 117(1): 161-165, 2014

Bevacizumab for recurrent primary central nervous system lymphoma: a new treatment?. Neuro-Oncology 17(12): 1648-1649, 2016

Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project. Haematologica 98(5): 808-813, 2013

Recurrent Primary Central Nervous System Lymphoma Mimicking Neurodegenerative Disease. Neurologia Medico-Chirurgica 35(6): 360-363, 1995

Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma. No Shinkei Geka. Neurological Surgery 28(9): 789-794, 2000

Recurrent primary central nervous system lymphoma complicated by lymphomatous metastases. Neurology 50(4 SUPPL 4): A269, April, 1998

Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma. Neuro-Oncology 20(8): 1092-1100, 2018

Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis. Oncology Reports 5(2): 521-525, 1998

Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. International Immunology 22(11): 875-887, 2011

Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 45(7): 1556-1557, 1980

Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma. Yonsei Medical Journal 52(6): 1031-1034, 2012

Primary central nervous system lymphoma mimicking recurrent depressive disorder: A case report. Oncology Letters 9(4): 1819-1821, 2015

Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leukemia and Lymphoma 54(1): 58-61, 2013